CAG Webinar Program
Our webinar program covers a wide array of GI-focused topics with outlined learning objectives to meet the educational needs of CAG members, including Adult and Pediatric Gastroenterologists, Basic Scientists, and Trainees.
Watching recordings is considered a Section 2: Individual Learning activity by the Royal College of Physicians and Surgeons of Canada Maintenance of Certification program. Each recording is eligible for .5 hours of Section 2 credits.
Webinar recordings are available to CAG members. Log in to MyCAG to start watching.
Already logged in? Watch Now. Not a CAG member? Become one!
Available webinars:
CAG/AbbVie/Amgen/Ferring/J&J/Pfizer/Pendopharm/Takeda
IBD Update Post ECCO 2025
Featuring:
- Dr. Waqqas Afif, McGill University
- Dr. Vipul Jairath, Western University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Reena Khanna, Western University
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with AbbVie Corporation, Amgen, Ferring Canada, J&J Innovative Medicine, Pfizer Canada, Pendopharm, and Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/AbbVie/J&J/Pfizer/Takeda
IBD Update Post UEGW 2024
Featuring:
- Dr. John Marshall, McMaster University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Sally Lawrence, BC Children's Hospital
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with AbbVie Corporation, J&J Innovative Medicine, Pfizer Canada, Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update Post DDW 2024
Featuring:
- Dr. Aline Charabaty, Johns Hopkins School of Medicine
- Dr. Waqqas Afif, McGill University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Cynthia Seow, University of Calgary
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update from ECCO 2024
Featuring:
- Dr. Brian Feagan, Western University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Reena Khanna, Western University
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Janssen
AI in IBD and Beyond
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC, FACG, CAGF
- Alan Barkun, MD, CM, FRCPC, FACP, FACG, AGAF, MSc
- Peter Bossuyt, MD, PhD
- Vipul Jairath, MBChB, DPhil
- Kerri Novak, MD, FRCPC
- Michael F. Byrne, MD, MA, FRCPC, MRCP
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe the use of AI in IBD risk stratification and prognostication
- Integrate AI into IBD scoring systems in their clinical practice
- Employ AI to help personalize their approach to patient care
CAG/Incyte
CHOLABORATE: Updated Approaches to Cholangiocarcinoma Management
Featuring:
- Avijit Chatterjee, MD
- Pushpa Sathya, MD
- Michael Carter, MD
- Hatim Karachiwala, MD
Learning Objectives
Upon completion of this program, participants will be able to:
- Explain the diagnostic process and challenges for patients with cholangiocarcinoma (CCA)
- Describe methods to detect genomic abnormalities in CCA and the tissue requirements to ensure successful genomic testing
- Apply knowledge of the evolving treatment options for patients with CCA in clinical practice
CAG/Pfizer
Settling Behaviour in IBD
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC
- Yvette Leung, MD, FRCPC
Learning Objectives
Upon completion of this program, participants will be able to:
- Identify patients with IBD who exhibit settling behaviour with their treatment
- Identify barriers and areas of discordance in both communication and treatment priorities between patients and gastroenterologists
- Apply appropriate treatment strategies and tools aimed at addressing settling behaviour in patients with inadequately controlled IBD through case discussion